Synexus Expands in Germany with New Center in Bochum
Synexus has opened a research center in Bochum.
Synexus has opened a research center in Bochum, which is the company’s fourth in Germany and its 23rd in total. The clinic has moved from a much smaller site in Bochum and is situated in the historic Kortum House. The five hundred square meter clinic runs primary care clinical trials for major clinical research organizations and pharmaceutical companies and provides facilities for up to six professional investigators.
“Germany is one of our foremost locations for running clinical trials with its excellent medical expertise, a history of running clinical trials and a large population,” said Christophe Berthoux, CEO of Synexus. “Europe continues to be a favored region for our clients in the running of their global clinical trials and we are planning to further develop our business in Germany.”
The new clinic, which will be managed by Annette Kuehlenborg, is well placed for easy patient access because it is close to the main station and has parking facilities in the immediate vicinity. The company’s other German centers are in Frankfurt, Berlin, and Leipzig.
“This is a further step in our plan to update and expand our very successful network of clinics across Germany by providing modern clinics which benefit both our patients and our clients in pharma,” noted German Managing Director Christoph Dietrich. “Our success in bringing clinical trials to Germany is dependent on our ability to deliver patients and quality data. We have now put in place a sophisticated patient engagement program which improves the patient experience and it is these added-value extras which really pay dividends in terms of client success.”
All of Synexus’ 26 clinics across Europe and Africa focus particularly on undertaking cardiovascular, metabolic (diabetes and obesity), musculoskeletal, respiratory and central nervous system (dementia and pain) trials.
Read the full release here.
Phase III Trials Confirm Remibrutinib Effectively Reduces Chronic Spontaneous Urticaria Symptoms
March 6th 2025Phase III REMIX-1 and REMIX-2 trials demonstrated that remibrutinib, an oral BTK inhibitor, significantly reduced chronic spontaneous urticaria symptoms in patients unresponsive to second-generation H1-antihistamines.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Data Show Efficacy of Tezspire Treating Chronic Rhinosinusitis with Nasal Polyps
March 4th 2025Phase III WAYPOINT trial shows Tezspire (tezepelumab) significantly reduces nasal polyp size and congestion severity in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, while also decreasing the need for surgery and systemic glucocorticoids.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Xolair Outperforms Oral Immunotherapy in Landmark Phase III OUtMATCH Food Allergy Trial
March 3rd 2025Xolair (omalizumab) shows superior efficacy and safety compared to multi-allergen oral immunotherapy in treating food allergies in the Phase III OUtMATCH trial, suggesting the potential to facilitate the introduction of allergenic foods into patients' diets after treatment.
